The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Chronic myelogenous leukemia (CML) is a human disease associated with a consistent chromosomal translocation that results in sequences from the c-abl locus on chromosome 9 being fused to sequences in a breakpoint cluster region (bcr) on chromosome 22. CML cells have two novel products: an 8.5-kilobase RNA transcript containing both abl and bcr and a 210-kilodalton phosphoprotein (P210) recognized by v-abl-specific antisera. To test whether the P210 is the product of the novel 8.5-kilobase bcr/abl fusion transcript, antibodies were prepared against c-abl and bcr determinants. By using these reagents and v-abl-specific antisera, it was demonstrated that the P210 in CML cells is indeed the protein product of the 8.5-kilobase transcript. By analogy to the gag/abl fusion protein of Abelson murine leukemia virus, the replacement of amino terminal c-abl sequences by bcr sequences in P210 may create a transforming protein involved in CML. A 190-kilodalton phosphoprotein that is a candidate for the normal bcr protein was identified in both HeLa and K562 cells.
Ben-Neriah
Y
Y
Daley
G Q
GQ
Mes-Masson
A M
AM
Witte
O N
ON
Baltimore
D
D
D000011:Abelson murine leukemia virus / Q000235:genetics; D000818:Animals; D002904:Chromosomes, Human, 21-22 and Y; D002906:Chromosomes, Human, 6-12 and X; D006367:HeLa Cells / Q000378:metabolism; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D007951:Leukemia, Myeloid / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*; D009857:Oncogenes; D010677:Philadelphia Chromosome; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011817:Rabbits / Q000276:immunology
D007106:Immune Sera; D009363:Neoplasm Proteins; D011505:Protein-Tyrosine Kinases